Pacific Biosciences of California Management

Management criteria checks 2/4

Pacific Biosciences of California's CEO is Christian O. Henry, appointed in Sep 2020, has a tenure of 3.67 years. total yearly compensation is $6.62M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €472.56K. The average tenure of the management team and the board of directors is 3.3 years and 11.3 years respectively.

Key information

Christian O. Henry

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage	10.1%
CEO tenure	3.7yrs
CEO ownership	0.1%
Management average tenure	3.3yrs
Board average tenure	11.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Christian O. Henry's remuneration changed compared to Pacific Biosciences of California's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$307m
Sep 30 2023	n/a	n/a	-US$309m
Jun 30 2023	n/a	n/a	-US$319m
Mar 31 2023	n/a	n/a	-US$321m
Dec 31 2022	US$7m	US$667k	-US$314m
Sep 30 2022	n/a	n/a	-US$299m
Jun 30 2022	n/a	n/a	-US$206m
Mar 31 2022	n/a	n/a	-US$175m
Dec 31 2021	US$3m	US$650k	-US$181m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$59m
Dec 31 2020	US$13m	US$195k	US$29m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$51m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$100k	n/a	-US$84m
Sep 30 2019	n/a	n/a	-US$115m
Jun 30 2019	n/a	n/a	-US$111m
Mar 31 2019	n/a	n/a	-US$109m
Dec 31 2018	US$88k	n/a	-US$103m

Compensation vs Market: Christian O.'s total compensation ($USD6.62M) is above average for companies of similar size in the German market ($USD1.04M).

Compensation vs Earnings: Christian O.'s compensation has increased whilst the company is unprofitable.

CEO

Christian O. Henry (55 yo)

3.7yrs

Tenure

US$6,616,251

Compensation

Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christian O. Henry	President	3.7yrs	US$6.62m	0.11% $ 472.6k
Susan Kim	Chief Financial Officer	3.7yrs	US$2.62m	0.036% $ 153.4k
Mark Van Oene	Chief Operating Officer	3.3yrs	US$6.56m	0.10% $ 440.3k
Jeff Eidel	Chief Commercial Officer	1.8yrs	US$5.80m	0.032% $ 137.1k
Stephen Turner	Co-Founder	23.8yrs	US$466.76k	no data
Michele Farmer	VP & Chief Accounting Officer	3yrs	no data	0.012% $ 49.6k
Trevin Rard	Head of Investor Relations	no data	no data	no data
Brett Atkins	General Counsel & Corporate Secretary	no data	no data	no data
Natalie Welch	Chief People Officer	no data	no data	no data
Denis Zaccarin	Senior Vice President of Research & Development	1.1yrs	US$1.48m	no data
Mike Goloubef	Senior Vice President of Manufacturing & Quality	no data	no data	no data

3.3yrs

Average Tenure

50yo

Average Age

Experienced Management: P09's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christian O. Henry	President	5.8yrs	US$6.62m	0.11% $ 472.6k
William Ericson	Independent Director	20.3yrs	US$259.00k	0.0069% $ 29.6k
Lucy Shapiro	Independent Director	11.7yrs	US$255.00k	0% $ 0
John Milligan	Independent Chairman	10.8yrs	US$297.00k	0.040% $ 173.3k
Harry Gray	Member of the Scientific Advisory Board	no data	no data	no data
Joseph Bonventre	Member of the Scientific Advisory Board	no data	no data	no data
Randall Livingston	Independent Director	15.3yrs	US$265.00k	0% $ 0
Harold Craighead	Member of the Scientific Advisory Board	no data	no data	no data
Roger Kornberg	Member of the Scientific Advisory Board	no data	no data	no data
Watt Webb	Member of the Scientific Advisory Board	no data	no data	no data
Kenneth Johnson	Member of the Scientific Advisory Board	no data	no data	no data
Jay Shendure	Chairman of Scientific Advisory Board	1.5yrs	no data	no data

11.3yrs

Average Tenure

69yo

Average Age

Experienced Board: P09's board of directors are seasoned and experienced ( 11.3 years average tenure).

Pacific Biosciences of California Management

Management criteria checks 2/4

Key information

Recent management updates

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Insider recently bought €162k worth of stock

President recently sold €445k worth of stock

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Recent updates

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors

Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) completed the acquisition of Omniome, Inc.

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) acquired Circulomics, Inc.

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2020)

Senior Fellow & Director Michael Hunkapiller has left the company

VP & Chief Accounting Officer has left the company

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.008 profit in 1Q 2020)

Pacific Biosciences of California, Inc. Launches New HiFi Sequencing Workflow

Revenue beats expectations

Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019)

VP & Chief Accounting Officer recently sold €124k worth of stock